Exagen Inc. Common Stock
XGNExagen Inc. (XGN) is a biotechnology company focused on developing and commercializing diagnostic tests to improve the management of autoimmune diseases. The company specializes in innovative testing solutions that aid in diagnosing conditions such as lupus and rheumatoid arthritis, aiming to enhance patient outcomes through precise and early detection.
Company News
Exagen Inc. (Nasdaq: XGN) announced preliminary 2025 financial results showing record full-year revenue of $66M-$67M, representing 19-20% year-over-year growth. The company achieved AVISE CTD test volume growth of 11% and trailing 12-month average selling price expansion of at least $30 compared to 2024. Year-end cash position strengthened to $32...
Exagen Inc., a leading autoimmune diagnostics company, announced participation in two upcoming investor conferences in November 2025, highlighting its commitment to showcasing its innovative autoimmune testing solutions.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).
Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
